

Supplementary Table 1. ADAS-Cog13 results in the placebo-controlled and LTE periods.

		Placebo (High Dose Late Start after week 78) (N=214)	Low Dose (N=116)	Intermediate Dose (N=106)	High Dose (N=214)
Week 24	n	204	109	102	207
	Adjusted mean change from baseline	0.77	1.60	0.83	1.16
	95% CI	(-0.037, 1.577)	(0.597, 2.594)	(-0.193, 1.848)	(0.361, 1.951)
	p-value (compared with placebo/ high dose late- start)	N/A	0.1463	0.9212	0.4146
Week 52	n	174	98	95	179
	Adjusted mean change from baseline	2.23	3.28	3.84	3.21
	95% CI	(1.221, 3.236)	(2.006, 4.555)	(2.545, 5.142)	(2.217, 4.207)
	p-value (compared with placebo/ high dose late- start)	N/A	0.1673	0.0371	0.1252
Week 78	n	170	96	90	173
	Adjusted mean change from baseline	5.83	7.54	7.58	7.50
	95% CI	(4.602, 7.054)	(5.963, 9.113)	(5.956, 9.195)	(6.292, 8.717)
	p-value (compared with placebo/ high dose late- start)	N/A	0.0765	0.0760	0.0397
Week 104 (LTE)	n	126	75	72	132
	Adjusted mean change from baseline	7.98	9.55	8.78	9.78
	95% CI	(6.426, 9.533)	(7.542, 11.553)	(6.723, 10.837)	(8.247, 11.307)
	p-value (compared with placebo/ high dose late- start)	N/A	0.2105	0.5296	0.0907

Analysis was performed using mixed model repeated measures with data from the placebo-controlled period and LTE period. Analyses were two-sided at 5% significance level. No adjustments were made for multiple comparisons.